Updating results

234 results for Myocardial Infarction

Sort: Relevance | Date

Myocardial infarction with ST-segment elevation

Everything NICE has said on the acute management of myocardial infarction with ST-segment elevation in an interactive flowchart

NICE Pathway Published July 2013 Last updated November 2018

Myocardial infarction: rehabilitation and preventing further cardiovascular disease

Everything NICE has said on cardiac rehabilitation and preventing cardiovascular disease after myocardial infarction in an interactive flowchart

NICE Pathway Published November 2013 Last updated May 2018

Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease (CG172)

This guideline covers cardiac rehabilitation and preventing further cardiovascular disease in people aged 18 and over who have had a myocardial infarction. It aims to promote the health of people who have had an MI by encouraging them to attend a cardiac rehabilitation programme and advising them on a healthy lifestyle. It also includes advice on drug therapy.

Clinical guideline Published November 2013

Myocardial infarction with ST-segment elevation: acute management (CG167)

This guideline covers care and treatment of people aged 18 and over with a type of heart attack known as spontaneous onset of myocardial infarction with ST-segment elevation (STEMI). It aims to ensure that adults with STEMI are assessed and treated as soon as possible to minimise the damage to their heart. It also aims to help commissioners and healthcare professionals configure services so that people with STEMI can have the best outcomes.

Clinical guideline Published July 2013

Secondary prevention after a myocardial infarction (QS99)

This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.

Quality standard Published September 2015

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

Technology appraisal guidance Published November 2003 Last updated July 2011

Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

Evidence-based recommendations on bivalirudin (Angiox) for treating ST-segment-elevation myocardial infarction (STEMI)

Technology appraisal guidance Published July 2011

Unstable angina and NSTEMI: early management (CG94)

This guideline covers treatments for people aged 18 and over with unstable angina (recurring chest pain) or a type of heart attack called non-ST-segment-elevation myocardial infarction (NSTEMI). It aims to ensure that people get treatment quickly. It recommends that as soon as NSTEMI or unstable angina is diagnosed, healthcare professionals assess people for risk of more serious heart problems in the future to guide their treatment.

Clinical guideline Published March 2010 Last updated November 2013

Acute coronary syndromes in adults (QS68)

This quality standard covers diagnosing and managing acute coronary syndromes in adults (aged 18 and over). Acute coronary syndromes are medical emergencies that include myocardial infarction (heart attack) and unstable angina (unexpected, severe chest pain). It describes high-quality care in priority areas for improvement.

Quality standard Published September 2014

Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in

Technology appraisal guidance Published October 2002

BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups (PH46)

This guideline covers the link between body mass index (BMI) and waist circumference and the risk of disease among adults from black, Asian and other minority ethnic groups in the UK. The aim was to determine whether lower cut-off points should be used for these groups as a trigger for lifestyle interventions to prevent conditions such as diabetes, myocardial infarction or stroke.

Public health guideline Published July 2013

Chest pain of recent onset: assessment and diagnosis (CG95)

This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.

Clinical guideline Published March 2010 Last updated November 2016

Hyperglycaemia in acute coronary syndromes: management (CG130)

This guideline covers managing hyperglycaemia in the first 48 hours for adults admitted to hospital for acute coronary syndromes. It aims to improve initial management of hyperglycaemia and ensure that adults are given advice on their diabetes risk and how to reduce it.

Clinical guideline Published October 2011

Chest pain

Everything NICE has said on assessing and managing recent suspected cardiac chest pain including acute coronary syndromes and stable angina in an interactive flowchart

NICE Pathway Published November 2016 Last updated June 2019

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)

Technology appraisal guidance Published July 2014

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events

Technology appraisal guidance Published December 2010

Ticagrelor for the treatment of acute coronary syndromes (TA236)

Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes

Technology appraisal guidance Published October 2011

Stable angina: management (CG126)

This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

Clinical guideline Published July 2011 Last updated August 2016

Acute heart failure: diagnosis and management (CG187)

This guideline covers diagnosing and managing acute heart failure or possible acute heart failure in people aged 18 and over. It aims to improve the immediate care of someone who is acutely unwell as a result of heart failure.

Clinical guideline Published October 2014

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

Technology appraisal guidance Published March 2015

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

Technology appraisal guidance Published February 2013

Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG494)

Evidence-based recommendations on endoscopic saphenous vein harvest for coronary artery bypass grafting in coronary artery disease (CAD)

Interventional procedures guidance Published June 2014

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

MiraQ for assessing graft flow during coronary artery bypass graft surgery (MTG8)

Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery

Medical technologies guidance Published November 2011 Last updated February 2018

Bioresorbable stent implantation for treating coronary artery disease (IPG492)

Evidence-based recommendations on bioresorbable stent implantation for treating coronary artery disease (CHD)

Interventional procedures guidance Published May 2014

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)

Technology appraisal guidance Published September 2015

Transmyocardial laser revascularisation for refractory angina pectoris (IPG301)

Evidence-based recommendations on transmyocardial laser revascularisation (TMLR) for refractory angina pectoris

Interventional procedures guidance Published May 2009

Percutaneous laser revascularisation for refractory angina pectoris (IPG302)

Evidence-based recommendations on percutaneous laser revascularisation (keyhole surgery) for refractory angina pectoris

Interventional procedures guidance Published May 2009

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Totally endoscopic robotically assisted coronary artery bypass grafting (IPG128)

Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB)

Interventional procedures guidance Published June 2005

Off-pump coronary artery bypass grafting (IPG377)

Evidence-based recommendations on off-pump coronary artery bypass grafting (CABG) to treat coronary artery disease (CAD)

Interventional procedures guidance Published January 2011

Percutaneous laser coronary angioplasty (IPG378)

Evidence-based recommendations on percutaneous laser coronary angioplasty to treat blocked coronary arteries

Interventional procedures guidance Published January 2011

Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary

Technology appraisal guidance Published September 2002 Last updated March 2010

Acute coronary syndromes

In development [GID-NG10085] Expected publication date: 14 May 2020

NICE guideline In development

ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

Advice ClearWay RX for drug delivery to coronary artery thrombotic lesions to aid local decision-making

Medtech innovation briefing Published March 2016

Implanting a baroreceptor stimulation device for resistant hypertension (IPG533)

Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension

Interventional procedures guidance Published October 2015

Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

Technology appraisal guidance Published June 2013 Last updated November 2016

Familial hypercholesterolaemia: identification and management (CG71)

This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.

Clinical guideline Published August 2008 Last updated November 2017

HumiGard for preventing inadvertent perioperative hypothermia (MTG31)

Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia in patients having abdominal surgery

Medical technologies guidance Published February 2017

Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Technology appraisal guidance Published June 2014

Renin-angiotensin system drugs: dual therapy (KTT2)

hypertension , chronic heart failure , chronic kidney disease , myocardial infarction – secondary prevention , type 1 diabetes and type...

Key therapeutic topic Published January 2015 Last updated February 2016

Coronary revascularisation: Cangrelor (ESNM63)

Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

Evidence summary Published November 2015

The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

Advice on the use of the PressureWire fractional flow reserve measurement system for coronary artery disease to aid local decision-making

Medtech innovation briefing Published February 2014

Ultrasound-guided foam sclerotherapy for varicose veins (IPG440)

Evidence-based recommendations on ultrasound-guided foam sclerotherapy for treating varicose veins

Interventional procedures guidance Published February 2013

Naltrexone–bupropion for managing overweight and obesity (TA494)

Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults

Technology appraisal guidance Published December 2017

Familial hypercholesterolaemia

Everything NICE has said on familial hypercholesterolaemia in an interactive flowchart

NICE Pathway Published August 2013 Last updated July 2018

Admissions rates due to myocardial infarction in people with diabetes

Admissions rates due to myocardial infarction in people with diabetes Subject(s): Diabetes Date of publication: 01

CCG indicator Published July 2016